$1.08
-0.05-4.42%
Last update: Nov 10, 7:06 PM
Aptevo Therapeutics Inc
APVONASDAQ
Aptevo Therapeutics fell 96.0% from $27.00 to $1.08, behind the S&P 500's +9.8%. Its worst day was Dec 26 (−34.7%), and its low came Nov 10 at $1.08.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Aptevo Therapeutics shares fell 34.7%, while the S&P 500 fell 0.0%.
−34.7%, the year's worst day · S&P 500 0.0%
Story events cover the past 12 months · Times ET
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidineSEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutics Inc.
−21.2% · S&P 500 −0.2%
EPS of $-6.23 beat the $-8.09 estimate on $0.00 revenue.
+0.9% · S&P 500 −1.8%
EPS of $-6.41 missed the $-5.60 estimate on $0.00 revenue.
+0.7% · S&P 500 +0.8%
EPS of $-5.31 beat the $-6.16 estimate on $0.00 revenue.
−13.8% · S&P 500 −0.2%
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success
−34.2% · S&P 500 +1.0%
Aptevo Therapeutics shares fell 14.7%, while the S&P 500 rose 0.6%.
−14.7% · S&P 500 +0.6%
Where it ended: a close of $1.08 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-3.58).
Nothing in the past 12 months.
All APVO analyst actionsNothing in the past 12 months.
All APVO dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for APVO and SPY from Benzinga historical bars. Not investment advice.
